BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10 | $8 | $7 | $5 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $2 | $3 | $2 | $2 |
| Enterprise Value | $11 | $10 | $8 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9.2% | -5.2% | 1,882.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.6% | 96.7% | 97.7% | 64.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -143.6% | -129.1% | -108.2% | -3,996.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -151.4% | -164.5% | -143.5% | -4,506.1% |
| EPS Diluted | -0.96 | -0.95 | -0.88 | -1.4 |
| % Growth | -1.1% | -8% | 37.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |